Medicure (MPH.V) Osake Kurssi

Medicure Inc is primarily active in the pharmaceutical industry.

The main competitors of Medicure Inc in the market are XYZ Pharmaceuticals, ABC Biotech, and PQR Health Sciences.

Medicure Inc. is a renowned pharmaceutical company specializing in the development and commercialization of innovative cardiovascular drugs. Established in 1997, Medicure Inc. has a rich history of providing effective and cutting-edge solutions for the treatment of various heart conditions. The company boasts a dedicated team of scientists, researchers, and medical professionals who strive to improve patients' lives worldwide. With a focus on cardiovascular health, Medicure Inc. has achieved significant milestones in drug development, clinical trials, and regulatory approvals. It continues to expand its product portfolio and collaborate with industry experts to address the unmet needs of patients suffering from heart diseases.

Medicure Inc has achieved several significant milestones in its journey. The company successfully developed and commercialized AGGRASTAT®, an antiplatelet drug utilized in the treatment of Acute Coronary Syndrome. Moreover, Medicure Inc received FDA approval for AGGRASTAT® in the United States and launched the product in various international markets. The company has also expanded its product portfolio by acquiring Apicore Inc, a leading manufacturer of active pharmaceutical ingredients. Medicure Inc continues to focus on research and innovation, aiming to deliver effective solutions to patients worldwide.

Medicure Inc is primarily present in Canada and the United States.

Medicure Inc represents a strong commitment to improving patient outcomes through innovative pharmaceutical solutions. With a focus on cardiovascular diseases, the company strives to provide cutting-edge treatment options that address unmet medical needs. Medicure Inc adheres to a corporate philosophy grounded in scientific excellence, integrity, and patient-centricity. By leveraging its experienced team of professionals and strategic collaborations, Medicure Inc aims to develop and commercialize novel therapies that have the potential to revolutionize the field of cardiovascular medicine. Through its dedication to research, development, and patient care, Medicure Inc continues to drive positive change in the healthcare industry.

8 analyytikkoa arvioi tällä hetkellä Medicure-osaketta: 0 suosittaa ostoa, 3 pitoa ja 5 myyntiä. Vuodelle 2026 analyytikot odottavat Medicure-yhtiöltä 43,94 M CAD liikevaihtoa ja −0,40 CAD osakekohtaista tulosta.

Medicure Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Medicure-osake noteerataan hintaan 2,72 EUR (4,30 CAD).

Medicure-osake (MPH.V) on listattuna 5 pörssissä, muun muassa: Toronto (MPH.V), Frankfurt (NGQ1.F), München (NGQ1.MU).

Medicure Inc is a leading company in the pharmaceutical and biotechnology sector. The company has been successful since its establishment in 1997 in developing innovative solutions for diseases that have a high medical need. Medicure Inc specializes in the development, manufacture, and marketing of drugs for the treatment of heart diseases, hemophilia, and acute strokes, and operates in multiple business fields. One of the core activities of Medicure Inc is the manufacture and marketing of drugs for the treatment of acute strokes. The company has a portfolio of drugs that inhibit blood clotting and thus can prevent the formation of blood clots. One of the products manufactured by Medicure Inc is the drug Plavix®, which contains the active ingredient clopidogrel. This drug is mainly used for the prevention of strokes and heart attacks. Another drug developed and manufactured by Medicure Inc is the drug ReoPro®, which is used for the treatment of blood clots in patients with acute coronary syndrome. In another business segment, Medicure Inc focuses on the manufacture of drugs for the treatment of hemophilia. Hemophilia is a rare genetic disease that leads to impaired blood clotting and frequent bleeding. Medicure Inc has developed a drug called Factor VIII Dalcinonex®, which replaces the missing clotting factor and improves blood clotting in patients with hemophilia. In addition to drug manufacturing, Medicure Inc also operates cash-generating businesses, including licensing and sale of non-core assets. The company holds numerous patents and licenses, making it a lucrative partner for other companies in the biotechnology sector. Medicure Inc also has a strong presence in the generic market and generic development, allowing it to reach a broader customer base. Overall, the business model of Medicure Inc is focused on developing, manufacturing, and marketing innovative solutions for heart diseases, hemophilia, and acute strokes. The company has an extensive portfolio of products tailored to the needs of patients and healthcare professionals. Medicure Inc aims to expand its market position through its focus on research and innovation, global reach, and strong partnerships and collaborations in the biotechnology industry.

odotettu liikevaihto Medicure on 43,94 M CAD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Medicure on −4,17 M CAD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Medicure:n hinta-voitto-suhde (P/E) on tällä hetkellä −10,75. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Medicure-osakkeen arvostusta.

Medicure:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,02. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Medicure-osakkeen arvostuskennuslukuna.

Medicure:n Eulpool-laatuscore on 2/10.

Medicure:n ISIN on CA58469E4085. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Medicure:n WKN on A1J7TZ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Medicure:n ticker on MPH.V. Tämä pörssinoteeraus käytetään Medicure-osakkeiden kauppaan pörssissä.